Kazunori Ochiai - Concepedia

Author

Kazunori Ochiai

Jikei University School of Medicine ORCID

Also Known As

B.K. Kim, H. Nagashima, K OCHIAI, K Ochiai, K. Alektiar, K. OCHIAI, K. Ochiai, KAZUNORI OCHIAI, Kazunori OCHIAI, Kazunori Ochiai

202

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

Jikei University School of Medicine Keio University Iwate Medical University Kindai University Niigata Cancer Center Hospital

About

Kazunori Ochiai is an author at Jikei University School of Medicine specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	32	2.7K
2	Public Health	5	5	201
3	Cell Biology	5	5	595
4	Health Sciences	3	3	94
5	Endocrinology	2	2	43

Kazunori Ochiai

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Noriyuki Katsumata, Makoto Yasuda, Fumiaki Takahashi, The Lancet Advanced Ovarian CancerMedicineMetronomic TherapyPharmacologyDose-dense Paclitaxel	2009	731
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial Noriyuki Katsumata, Makoto Yasuda, Seiji Isonishi, The Lancet Oncology Gastrointestinal OncologyConventional PaclitaxelMedicineMetronomic TherapyDose-dense Paclitaxel	2013	468
Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells Aikou Okamoto, Takashi Nikaido, Kazunori Ochiai, Clinical Cancer Research	2005	394
Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Kenji Ono, Toshihiro Tanaka, Tatsuhiko Tsunoda, PubMed Malignant DiseaseDna Microarray ConsistingGeneticsMedicineCdna Microarray	2000	311
Outcomes of Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Proposal for Patient Selection Toyomi Satoh, Masayuki Hatae, Yoh Watanabe, Journal of Clinical Oncology	2010	199
A Novel Gene, CRR9, Which Was Up-Regulated in CDDP-Resistant Ovarian Tumor Cell Line, Was Associated with Apoptosis Kazue Yamamoto, Aikou Okamoto, Seiji Isonishi, Biochemical and Biophysical Research Communications Novel GeneMedicineApoptosisCell DeathCell Biology	2001	151
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse Ignace Vergote, Deborah K. Armstrong, Giovanni Scambia, Journal of Clinical Oncology	2016	149
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions Amer Karam, Jonathan A. Ledermann, Jae‐Weon Kim, Annals of Oncology MedicineGynecologic Cancer IntergroupCancer ManagementGynecologyCancer Treatment	2017	149
Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Masaru Sakamoto, Ayako Kondo, Kenta Kawasaki, PubMed	2001	109
Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer Miho Takao, Aikou Okamoto, Takashi Nikaido, Oncology Reports	2007	99

Page 1